profit from every $100 of sales.
$0$100
Lexaria Bioscience
$4.64-0.85% today
+314.3% in 1 year
1-year low $0.531-year high $15.90
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Lexaria Bioscience sold, what it kept, and what it did with the cash.
Sales went from $255,397 in 2022 to $705,923 in 2025, with -$11.9 million of profit last year.
SalesProfit
Lexaria Bioscience vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Lexaria Bioscience | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads Lexaria Bioscience's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 1 | |
| 0 | 0 | 0 | 1 | |
| -7 | -7 | -6 | -12 | |
| -7 | -6 | -6 | -12 | |
| -7 | -7 | -6 | -12 | |
| -1.24 | -1.01 | -0.47 | -0.66 | |
| 71.9% | 86.1% | 99.0% | 99.6% | |
| -2,591.7% | -2,888.5% | -1,239.2% | -1,683.0% | |
| -2,846.3% | -2,946.4% | -1,248.2% | -1,686.0% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 8 | 3 | 9 | 4 |
| Cash | 6 | 1 | 6 | 2 |
| Total debt | 0 | 0 | 0 | 0 |
| Total liabilities | 0 | 0 | 1 | 2 |
| 8 | 3 | 8 | 3 | |
| 6 | 7 | 12 | 18 | |
| -65.4% | -160.9% | -55.6% | -302.9% | |
| -91.5% | -218.9% | -72.1% | -398.1% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -5 | -6 | -5 | -10 | |
| 0 | 0 | 0 | 0 | |
| -5 | -6 | -5 | -11 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 1 | 0 | 0 | 1 |
Valuation
- –
- –
- –
- 2.3×
- 13.8×
- –
- –
- -107.9%
- -121.8%
- 0.0%
Profitability
- 99.6%
- -1,683.0%
- -1,686.0%
- -2,567.4%
- -146.7%
- -156.7%
- -190.1%
- -146.9%
- -147.5%
- 1,561.5%
Growth
- +40.3%
- –
- −109.4%
- –
- +42.3%
Financial health
- -0.1×
- 0.01
- 1.5%
- –
- 26.88
- 26.88
- 0.06
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 14%of 889
What analysts expect
- Average price target
- $1.50
- Range
- $1.50 – $1.50
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Apr 13, 2026 | -0.06 | -0.10 | +40.0% |
| Jan 13, 2026 | -0.07 | -0.13 | +46.2% |
| Nov 26, 2025 | -0.13 | -0.16 | +18.8% |
| Jul 14, 2025 | -0.21 | -0.15 | −40.0% |
| Apr 14, 2025 | -0.15 | -0.16 | +6.3% |
| Jan 10, 2025 | -0.16 | -0.12 | −33.3% |
| Nov 26, 2024 | -0.15 | -0.11 | −36.4% |
| Jul 12, 2024 | -0.13 | -0.10 | −30.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
55No pass
Philip Fisher
60Pass
Peter Lynch
100Pass
Joel Greenblatt
2No pass
Charlie Munger
56No pass
Terry Smith
58No pass
Questions about Lexaria Bioscience
Is Lexaria Bioscience a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Lexaria Bioscience AI analysis
What does Lexaria Bioscience do?
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. It is in Biotechnology.
Does Lexaria Bioscience pay a dividend?
No. Lexaria Bioscience does not pay a dividend at the moment.
Is Lexaria Bioscience stock halal?
Yes. Lexaria Bioscience passes our halal screen: its business is permitted and its debt is 1% of its market value, under the 30% limit. How we check
How has Lexaria Bioscience stock done over the past year?
Up 314.3% over the past twelve months, to $4.64. It traded between $0.53 and $15.90 and is 70.8% below its high.
Who are Lexaria Bioscience's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Lexaria Bioscience's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.